



(51) International Patent Classification:

A61K 38/17 (2006.01) C12N 15/86 (2006.01)
C07K 14/71 (2006.01)

(21) International Application Number:

PCT/US2024/052996

(22) International Filing Date:

25 October 2024 (25.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/593,800 27 October 2023 (27.10.2023) US

(71) Applicant: **REPLICATE BIOSCIENCE, INC.** [US/US];
11558 Sorrento Valley Rd., Suite 6, San Diego, California
92121 (US).

(72) Inventors: **WANG, Nathaniel Stephen**; c/o Replicate Bio-
science, Inc., 11558 Sorrento Valley Rd., Ste. 6, San Diego,
California 92121 (US). **MAINE, Christian**; c/o Replicate
Bioscience, Inc., 11558 Sorrento Valley Rd., Ste. 6, San

Diego, California 92121 (US). **ALIAHMAD, Parinaz**; c/o
Replicate Bioscience, Inc., 11558 Sorrento Valley Rd., Ste.
6, San Diego, California 92121 (US). **MIYAKE-STONER,
Shigeki Joseph**; c/o Replicate Bioscience, Inc., 11558 Sor-
rento Valley Rd., Ste. 6, San Diego, California 92121 (US).

(74) Agent: **GOTTFRIED, Lynn F.** et al.; Mintz Levin, One
Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: COMPOSITIONS AND METHODS FOR EXPRESSION OF EGFR




FIG. 1

(57) Abstract: The present disclosure relates to modified viral genomes or self-replicating RNAs (srRNAs) and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for modulating a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and/or treating various health conditions and diseases.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

12 June 2025 (12.06.2025)